Atara Biotherapeutics, Inc. (ATRA) — research page
US · us-cm-kg/NASDAQ/ATRA · as of 2026-11-08
Identity and listing
The issuer is Atara Biotherapeutics, Inc., listed on NASDAQ under ticker ATRA, with ISIN US0465132068 and LEI 549300WBXUXZRE03MS38. Its security type is Corporate, its sector is 2836 Biological Products, (No Diagnostic Substances), and its jurisdiction is United States, Delaware. Segment is not on the record. Status: listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | Atara Biotherapeutics, Inc. | source · 2026-11-08 |
| exchange | NASDAQ | source · 2026-11-08 |
| ticker | ATRA | source · 2026-11-08 |
| ISIN | US0465132068 | source · 2026-11-08 |
| LEI | 549300WBXUXZRE03MS38 | source · 2026-11-08 |
| security type | Corporate | source · 2026-11-08 |
| segment | not on the record | |
| sector | 2836 Biological Products, (No Diagnostic Substances) | source · 2026-11-08 |
| jurisdiction | United States — Delaware | source · 2026-11-08 |
| status | listed, not halted | source · 2026-11-08 |
The disclosure read
The record holds 69 filings in the twelve months to 2026-11-08, across 40 filing days. The median gap between filing days is 3 days. Days from the latest filing to the record date are 65; the latest filing is dated 2026-09-04 and is of type directors_dealings. The NASDAQ exchange median is 52 filings, a median cadence gap of 6.0 days, and a median latency of 5.0 days. The sector median is 65.5 filings, a median cadence gap of 5.5 days, and a median latency of 4.0 days.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 69 | 3 | 65 |
| exchange median: NASDAQ (4359 issuers) | 52 | 6 | 5 |
| sector median: 2836 Biological Products, (No Diagnostic Substances) (176 issuers) | 65.5 | 5.5 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-09-04 | directors_dealings | 4 | 4 — FORM 4 |
| 2026-08-26 | regulatory_filing | 144 | 144 |
| 2026-08-26 | directors_dealings | 4 | 4 — FORM 4 |
| 2026-08-14 | regulatory_filing | SCHEDULE 13G/A | SCHEDULE 13G/A |
| 2026-08-12 | results | 10-Q | 10-Q — 10-Q |
window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is DELOITTE & TOUCHE LLP, located in San Francisco, California. The record holds no auditor changes.
Events and halts
The record holds no listing, delisting or name-change lines. Domicile change is not on the record: EDGAR states no dated change of state of incorporation on a filing line. Segment move is not on the record: the exchanges' tier transfers are not EDGAR filings. Halt flag: listed, not halted.
Orderability
The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.
rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The field was found. The issuer's investor-relations page names 7 research houses: Canaccord Genuity, Cowen & Co., Evercore ISI, H.C. Wainwright, Mizuho Securities, Rodman & Renshaw, LLC, and Stifel.
| research house | analyst | source · read date |
|---|---|---|
| Canaccord Genuity | John Newman, Ph.D. | issuer page · 2026-11-11 |
| Cowen & Co. | Phil Nadeau, Ph.D. | issuer page · 2026-11-11 |
| Evercore ISI | Jonathan Miller, Ph.D. | issuer page · 2026-11-11 |
| H.C. Wainwright | Robert Burns | issuer page · 2026-11-11 |
| Mizuho Securities | Salim Syed | issuer page · 2026-11-11 |
| Rodman & Renshaw, LLC | Tony Butler, Ph.D. | issuer page · 2026-11-11 |
| Stifel | Benjamin Burnett, Ph.D. | issuer page · 2026-11-11 |
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The vintage is sealed. The issuer's sealed years are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.
Sources
10 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest (identity.isin)
- 10.3
- https://data.sec.gov/submissions/CIK0001604464.json (identity.jurisdiction)
- 10.4
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.5
- https://mcp.us-cm-kg.ai/events/NASDAQ/ATRA (the disclosure lines)
- 10.6
- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)
- 10.7
- https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/atra-20251231.htm (the auditor)
- 10.8
- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.9
- https://investors.atarabio.com/analyst-coverage (coverage)
- 10.10
- https://mcp.us-cm-kg.ai/record/NASDAQ/ATRA (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getissuer.ai/mcp with {"isin":"US0465132068"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:a6cf7e917bcb07ec.